FDA extends review of Amicus muscle disorder therapy for second time
Oct 28 (Reuters) – The U.S. Food and Drug Administration on Friday extended for the second time its review of Amicus Therapeutics Inc.’s (FOLD.O) experimental combination therapy to treat a muscle disorder called Pompe disease.
The agency blamed the delay on pandemic-related travel restrictions that kept it from conducting a required manufacturing site inspection before the decision was due.
Analysts from BTIG and Needham & Co said the extension will likely delay the launch of the therapy, AT-GAA, by a quarter.
Shares of the drugmaker were down 3% at $10.1 in extended trading.
Amicus was seeking approval for the expanded use of its drug migulstat, in combination with its lab-made protein cipaglucosidase alfa, which together form AT-GAA.
The U.S. FDA had in May extended its review of both the components, saying it needed more time to go through the data submitted by the company.
Pompe disease is a rare genetic condition in which the body is unable to break down the complex sugar glycogen, leading to a buildup of the same, which causes muscular impairment. The condition may also lead to heart failure in young patients.
Amicus and partner Wuxi are the latest companies to have their review extended by the FDA over COVID-related travel curbs. China-based Beigene (6160.HK) and Hutchmed Ltd. (0013.HK) as well as U.S.-based Coherus BioSciences Inc. (CHRS.O) saw similar extensions earlier in the year.
Our Standards: The Thomson Reuters Trust Principles.